These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 3219817)
1. Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019. Pfaller MA; Gerarden T; Yu M; Wenzel RP Diagn Microbiol Infect Dis; 1988 Sep; 11(1):1-9. PubMed ID: 3219817 [TBL] [Abstract][Full Text] [Related]
2. Susceptibility of nosocomial isolates of Candida species to LY121019 and other antifungal agents. Pfaller MA; Wey S; Gerarden T; Houston A; Wenzel RP Diagn Microbiol Infect Dis; 1989; 12(1):1-4. PubMed ID: 2714066 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of in vitro antifungal activity of LY121019. Hobbs M; Perfect J; Durack D Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):77-80. PubMed ID: 3132385 [TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species. Spitzer ED; Travis SJ; Kobayashi GS Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):80-1. PubMed ID: 3132386 [TBL] [Abstract][Full Text] [Related]
5. In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species. Smith KR; Lank KM; Dismukes WE; Cobbs CG Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):588-92. PubMed ID: 1655435 [TBL] [Abstract][Full Text] [Related]
6. Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis. Hall GS; Myles C; Pratt KJ; Washington JA Antimicrob Agents Chemother; 1988 Sep; 32(9):1331-5. PubMed ID: 3058017 [TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of cilofungin (LY121019) in comparison with amphotericin B. Meunier F; Lambert C; Van der Auwera P J Antimicrob Chemother; 1989 Sep; 24(3):325-31. PubMed ID: 2681118 [TBL] [Abstract][Full Text] [Related]
8. Activity of cilofungin (LY121019) against Candida species in vitro. Odds FC J Antimicrob Chemother; 1988 Dec; 22(6):891-7. PubMed ID: 3243737 [TBL] [Abstract][Full Text] [Related]
9. Fungicidal activity of cilofungin (LY121019) alone and in combination with anticapsin or other antifungal agents. Pfaller M; Gordee R; Gerarden T; Yu M; Wenzel R Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):564-7. PubMed ID: 2504601 [TBL] [Abstract][Full Text] [Related]
10. A study of the antifungal activity of LY121019, a new echinocandin derivative. Strippoli V; D'Auria FD; Simonetti N Chemioterapia; 1988 Feb; 7(1):33-7. PubMed ID: 3288366 [TBL] [Abstract][Full Text] [Related]
11. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
12. Effect of pH and buffer system on the in-vitro activity of five antifungals against yeasts. Gadea I; Cuenca M; Gegúndez MI; Zapardiel J; Valero ML; Soriano F J Antimicrob Chemother; 1997 Apr; 39(4):453-9. PubMed ID: 9145817 [TBL] [Abstract][Full Text] [Related]
13. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039 [TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole. Martín E; Parras P; Lozano MC Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species. Huang A; Edwards F; Bernard EM; Armstrong D; Schmitt HJ Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):697-9. PubMed ID: 2226501 [TBL] [Abstract][Full Text] [Related]
16. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study. Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K; Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267 [TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro antifungal susceptibility studies with 30 serotype A and B isolates of Candida albicans. Shadomy S; Shadomy HJ Diagn Microbiol Infect Dis; 1991; 14(1):21-2. PubMed ID: 2013207 [TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole. Morace G; Manzara S; Dettori G Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239 [TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of three antifungal susceptibility test methods against prospectively collected Candida species. Villareal KM; Cook RA; Galgiani JN; Wenzel RP; Pappas PG; Pottage JC; Gallis HA; Crane LR Diagn Microbiol Infect Dis; 1994 Feb; 18(2):89-94. PubMed ID: 8062537 [TBL] [Abstract][Full Text] [Related]
20. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012. Pfaller MA; Castanheira M; Messer SA; Jones RN Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]